Back

Impact of dapagliflozin on cardiometabolic outcomes after myocardial infarction according to baseline glycaemic status and body mass index: a DAPA-MI substudy

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: Pharmacotherapy in coronary artery disease: from bench to bedside (1) Pharmacotherapy ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Professor Robert Storey

University of Sheffield, Sheffield (United Kingdom of Great Britain & Northern Ireland)

8 More presentations in this session

Presentation thumbnail
Platelet membrane coated r-SAK to improve thrombolytic efficacy by targeting thrombus
Miss R. Hua (Nanjing, CN)
Abstract Slides Video
Presentation thumbnail
AtheroVax: a peptide vaccine with a therapeutic effect in animal model of chronic inflammation
Professor E. Ramacciotti (Santo Andre, BR)
Abstract Slides Video
Presentation thumbnail
Sodium-glucose cotransporter 2 inhibitor attenuates left ventricular dysfunction in post-myocardial infarction in rats via reducing cardiac mitochondrial impairment
Doctor C. Maneechote (Chiang Mai, TH)
Abstract Slides Video
Presentation thumbnail
A new free radical scavenger, resorcimoline, prevents ischaemia/reperfusion injury in the heart
Doctor K. Ueno (Oita, JP)
Abstract Slides Video
Presentation thumbnail
A randomized, double-blind, placebo-controlled, mechanistic trial on the safety, tolerability and pharmacodynamics of ninerafaxstat in patients with angina and chronic coronary syndrome
Doctor A. Saraste (Turku, FI)
Abstract Slides Video

Access the full session

Session thumbnail
Pharmacotherapy in coronary artery disease: from bench to bedside (1)

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024
You may be interested in
thumbnail
Congress Presentation
Efficacy and safety of dapagliflozin in non-diabetic patients with primary anterior ST-elevation myocardial infarction initiated in early hospital period
thumbnail
Congress Presentation
Effects of dapagliflozin in heart failure according to duration of type 2 diabetes: a patient-level meta-analysis of DAPA-HF and DELIVER
thumbnail
Congress Presentation
Comparison of dapagliflozin 10 mg versus empagliflozin 10 mg in heart failure patients without type 2 diabetes mellitus on top of triple guideline-directed medical therapy

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources